Prot#EDP 305-201: A Phase 2 Dose Ranging, Randomized, Double Blind, PlaceBo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis(PBC) with or without Inadequate Respons